Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00932321 · ClinicalTrials.gov registry record · Phase 3
Study of Safety and Efficacy of an Oral Contraceptive
A Phase 3 study, sponsored by Warner Chilcott.
- Completed
- Registry status
- Phase 3
- Development phase
- 938
- Enrollment target
NCT00932321: Completed Phase 3 study, sponsored by Warner Chilcott.
NCT00932321 is a Phase 3 study that has completed, run by Warner Chilcott. The registered enrollment target is 938 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (22% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00932321, a Phase 3 study, has completed, sponsored by Warner Chilcott.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 938 participants
- Enrollment target
Study Summary
This is a comparative study. The primary objective of the study is to assess the efficacy of a low dose oral contraceptive in the prevention of pregnancy. The secondary objectives are to assess the incidence of intracyclic bleeding of norethindrone acetate/ethinyl estradiol (NETA/EE) administered for 24 days and NETA/EE administered for 21 days; and to assess the safety and tolerability of the product.
Primary Outcome
Pearl Index = 1300 \* number of pregnancies/number of women-cycles of treatment
Interventions
- DRUG Norethindrone Acetate/Ethinyl Estradiol 24 Days
- DRUG Norethindrone Acetate /Ethinyl Estradiol 21 Days
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 938 participants |
| Start Date | 2004-01 |
| Est. Completion | 2004-11 |
| Phase | Phase 3 |
What the finished NCT00932321 record still lists
NCT00932321 is an interventional study that assigns participants to a tested intervention. The registered 938 participants enrollment target is mid-sized for trials with a published cap, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (22% higher).
The record links to 0 conditions, and to 2 interventions - of which Norethindrone Acetate/Ethinyl Estradiol 24 Days is the first listed.
NCT00932321 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00932321 about?
NCT00932321 is a clinical study titled "Study of Safety and Efficacy of an Oral Contraceptive". This is a comparative study. The primary objective of the study is to assess the efficacy of a low dose oral contraceptive in the prevention of pregnancy. The secondary objectives are to assess the incidence of intracyclic bleeding of norethindrone acetate/ethinyl estradiol (NETA/EE) administered fo...
What is the current status of trial NCT00932321?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 938 participants. The study started on 2004-01. Estimated completion is 2004-11.
What interventions are being tested in trial NCT00932321?
The interventions under investigation include: Norethindrone Acetate/Ethinyl Estradiol 24 Days (DRUG), Norethindrone Acetate /Ethinyl Estradiol 21 Days (DRUG).
Who is sponsoring clinical trial NCT00932321?
This trial is sponsored by Warner Chilcott, which has 53 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00932321's enrollment target sits among peer trials
938 338th of 2000 higher than 1,663 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03075696 · 940 participants · Phase 1
A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-cell Non-hodgkin's Lymphoma
- NCT06855277 · 940 participants · Phase 3
Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC
- NCT05519007 · 936 participants · NA
Rate of Total Joint Infection 90-day After Surgery Following Irrigation With Next Science No-Rinse Solution vs SOC Alone
- NCT06808334 · 942 participants
CLAiR Pivotal Study
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia